Skip to main content

Ataraxis AI

Category: AI in Healthcare

Ataraxis AI develops AI-native diagnostic tests to enhance cancer prognosis and improve treatment selection, starting with breast cancer. Ataraxis AI was founded in 2022. The company is led by Jan Witowski, MD, PhD. Based in New York, NY, USA. Team size: N/A. Total funding raised: $24M. Latest round: $20.4M Series A. Key investors include Giant Ventures, Obvious Ventures, AIX Ventures, Thiel Bio, Founders Fund, Floating Point, Bertelsmann Investments.

Founded
2022
Headquarters
New York, NY, USA
Team size
N/A
Total funding
$24M

Value proposition

Provides more accurate (up to 30% improvement over standard care) and personalized cancer diagnostics compared to traditional methods

Products and solutions

Ataraxis Breast

Unique value

Utilizes multi-modal AI foundation models to analyze diverse clinical and pathological data, creating diagnostic tests that are truly AI-native

Target customer

Healthcare providers, oncologists, and cancer patients

Industries served

Oncology, Precision Medicine, Biotechnology

Technology advantage

Achieves significantly higher predictive accuracy (approximately 30% better than standard diagnostics) through integration of advanced AI algorithms and multi-model ensembling

How they differentiate

Focuses exclusively on AI-native diagnostics, offering enhanced accuracy and personalized treatment guidance over conventional genomic and molecular assays

Main competitors

Guardant Health, Foundation Medicine, Exact Sciences

Key partnerships

Gundersen Health System, Karmanos Cancer Institute, NYU Langone Health, Providence Health & Services

Notable customers

Gundersen Health System, Karmanos Cancer Institute, NYU Langone Health

Major milestones

Emergence from stealth with $4M seed funding Clinical validation of Ataraxis Breast in a multi-site study involving over 7,500 patients Securing a $20.4M Series A to further advance clinical trials and expand diagnostic offerings

Growth metrics

Not publicly disclosed; rapid expansion in clinical validation and strategic partnerships

Market positioning

Positioned as a leader in the emerging field of AI-driven precision oncology diagnostics

Geographic focus

Global, with a strong initial emphasis in the United States

Patents and IP

Patent pending for its proprietary multi-modal AI diagnostic algorithm

About Jan Witowski, MD, PhD

Jan Witowski is a physician-scientist and entrepreneur with a background in medical image processing, particularly in the application of artificial intelligence to cancer imaging and the development of clinical diagnostic tools. He has held postdoctoral positions at prestigious institutions such as NYU Langone Health, Harvard Medical School, and Massachusetts General Hospital. In 2022, he co-founded Ataraxis AI, where he currently serves as CEO, leading the company's mission to develop AI-native diagnostic tests for cancer.

Official website: